Convatec Share Discussion Threads

[philanderer] 26/3/2019 12:51

Market report:

Medical equipment maker Convatec was the standout gainer on the FSTE 250 after Sweden's Dagens Industri reported that Swedish private equity group EQT may consider a bid for the company.

[philanderer] 25/3/2019 10:00

Peel Hunt upgrading from 'hold' to 'buy' ... tp 230p up from 150p

[philanderer] 10/3/2019 13:42

Questor: ConvaTec has lost its momentum so we must stomach our loss and sell

[nickthe saint] 23/2/2019 07:52

hi dbensimon,

yes i certainly think they present value at this price.

[dbensimon] 21/2/2019 10:53

Sure I am. Buy at this level for medium term.

[nickthe saint] 19/2/2019 09:29

This board is very quiet....

Is anyone still left on Board?

[johnv] 14/2/2019 13:16

On my watchlist now. Wait for the next profit warning and then buy.

[philanderer] 14/2/2019 09:58

Off the watchlist now.

[philanderer] 08/2/2019 10:32

Still waiting

Barclays Capital today reaffirms its underweight investment rating on ConvaTec Group Plc (LON:CTEC) and cut its price target to 148p (from 150p). Story provided by StockMarketWire.com

[robow] 22/1/2019 10:08

One of Peel Hunt's stock picks for 2019

Convatec (CTEC)
The depressed share price at medical products company Convatec has led to a rise in the dividend yield but the poor sentiment is unfounded.

Analyst Amy Walker retained her ‘hold’ recommendation and target price of 170p on the stock.

She said that ‘low visibility on earnings momentum has depressed the share price, leading to a rise in the dividend yield’ but even if the group misses her ‘conservative’ growth forecasts by 7% to 11% the company could still ‘yield at least 3% at the current share price, at the bottom of its target pay-out range’.

Walker is not pessimistic about the outlook for the company, stating that the demand for the medical technology firm’s products were ‘unlikely to change materially from their mid-single digit market growth rates’.

She added that the company can ‘support a stable to growing dividend’ but the most likely driver of volatility is the share price ‘which declined more than 30% on the most recent profit warning’.

[philanderer] 10/12/2018 10:11

Deutsche cuts target price to 130p from 180p - 'sell'

[philanderer] 27/11/2018 12:26

Still watching.


Barclays initiates coverage with 'underweight' and tp 150p

[philanderer] 30/10/2018 09:55

Numis upgrades Convatec to ‘buy’

Numis has upgraded medical technology company Convatec (CTEC) after an ‘unwarranted’ 35% fall in the share price.

Analyst Paul Cuddon upgraded his recommendation from ‘hold’ to ‘buy’ with a target price of 220p on the shares, which jumped 5.6% to 155p yesterday.

‘We do not think the loss of a chief executive and the decline in infusion devices warranted a 35% fall in Convatec’s share price, especially when the broader chronic care business is maintaining consistent 2% quarterly growth,’ he said.

‘We see full-year 2018 results, details on the self-help strategy and full-year 2019 outlook as key catalysts. The company trades on 10x enterprise value/earnings and offering sector leading free cashflow yield and so we upgrade to “buy”.’

[philanderer] 26/10/2018 17:24

Detail..

Medical products and technologies company ConvaTec fell on Friday as UBS downgraded the stock to 'neutral' from 'buy' and slashed the target price to 150p from 250p, pointing to a slowdown in the wound market - to which the group is over-exposed - and limited progress in the ostomy turnaround.

In addition, the bank highlighted concerns that EBIT margins will continue to decline, as investments are likely still required in internal controls, marketing and R&D, as well as capex.

UBS said it expects just 2% group organic sales growth in all future periods.

"We assume structural market share loss in Ostomy, with a 1% sales compound annual growth rate, ignoring significant investments aimed at delivering market growth of 5%. We also assume margins decline a further 100 basis points before stabilising at 22.5% from 2020, ignoring guidance of upside from 2020 from operating leverage and margin strategy to be announced in February 2019."

In its upside scenario, UBS sees fair value at 240p a share. However, without a CEO and after high senior staff turnover since IPO, it's hard to get comfort execution issues won't continue, it said.

Earlier this month, ConvaTec shares tumbled as it issued a profit and announced that CEO Paul Moraviec was stepping down.

[philanderer] 26/10/2018 08:37

Downgrade from UBS 'neutral' from 'buy' ... TP 150p cut from 250p

[philanderer] 25/10/2018 08:56

Peel Hunt 'hold' tp 170p cut from 220p

[philanderer] 22/10/2018 10:34

ConvaTec Group, down 3.0%. HSBC downgraded the wound dressings maker to Hold from Buy.

Target 165p cut from 245p

[giardap] 19/10/2018 20:18

You could get free samples from the other companies to try whilst running down your prescription. I need to declare I currently work for a UK manufacturer and 15 yrs ago used to work for ConvaTec R&D.

[giardap] 19/10/2018 18:49

Erogenous, get your Stoma Nurse to source alternative products for you to try.
There are a number of manufacturers out there in the UK.

[giardap] 18/10/2018 19:53

Bought today at £1.49 - prepared to sit and wait.Ageing society - a good long term buy. Unfortunatately this company was "fleeced" prior to and ramped at IPO by PE owners. Hopefully as their influence dwindles ConvaTec can get on with running its business with more attention to detail.